Presentation of Swedish Orphan Biovitrum's Interim Report July - September, 2010
(Thomson Reuters ONE) -
The third quarter 2010 report will be published around 8.30 a.m. (CET) October
26.
The Swedish Orphan Biovitrum AB (publ)´s Interim Report for the third quarter
2010 will be presented by Swedish Orphan Biovitrum´s CEO Martin Nicklasson and
CFO Göran Arvidson at an media and analyst meeting. The presentation will be
held in English and webcasted.
Time: Tuesday, October 26, 2010 at 3 p.m. (CET)
Venue: Grand Hôtel in Stockholm - Sweden (room: Mårten Vinge)
Coffee will be served
Registration:
Please register for participation to Maria Mattsson onmaria.mattsson(at)zvm.se or
by telephone +46 70 438 88 53.
Webcast:
The presentation will be webcasted, Tuesday October 26 at 3 p.m. (CET):
www.sobi.com.
Telephone dial in: UK: +44 (0)20 3043 2436, SE: +46 (0)8 505 598 53, US:
+1 866 458 40 87
The presentation material will be published on our web site after the meeting as
will the archived web cast, please go to: www.sobi.com.
Welcome!
Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50,erik.kinnman(at)sobi.com
Om Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and
inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues
2009e of about 2 BSEK and approximately 500 employees. The head office is
located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm.
For more information please visitwww.sobi.com.
[HUG#1453487]
Invitation Q3 in pdf format:
http://hugin.info/134557/R/1453487/394001.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 20.10.2010 - 13:22 Uhr
Sprache: Deutsch
News-ID 45943
Anzahl Zeichen: 0
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Presentation of Swedish Orphan Biovitrum's Interim Report July - September, 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
